Peter M. Anderson

7.2k total citations · 1 hit paper
129 papers, 4.3k citations indexed

About

Peter M. Anderson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Peter M. Anderson has authored 129 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 27 papers in Surgery. Recurrent topics in Peter M. Anderson's work include Sarcoma Diagnosis and Treatment (46 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (15 papers). Peter M. Anderson is often cited by papers focused on Sarcoma Diagnosis and Treatment (46 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (15 papers). Peter M. Anderson collaborates with scholars based in United States, United Kingdom and India. Peter M. Anderson's co-authors include Robert J. Desnick, Keith M. Skubitz, Diane E. Hasz, Andrea Hayes‐Jordan, Emmanuel Katsanis, Georgene Schroeder, Augusto C. Ochoa, Rajesh V. Lalla, Mark E. Wylam and Nancy E. Fitzgerald and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Peter M. Anderson

126 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Future Directions in the Treatment of Osteosarcoma

2021 160 citations Alannah Smrke, Peter M. Anderson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter M. Anderson United States	40	1.8k	1.1k	1.1k	684	564	129	4.3k
Kenzo Hiroshima Japan	46	4.4k 2.4×	2.3k 2.1×	1.1k 1.0×	240 0.4×	1.3k 2.3×	292	7.1k
K. Höffken Germany	36	848 0.5×	2.6k 2.3×	1.1k 1.0×	788 1.2×	425 0.8×	186	5.4k
D.C. Rijken Netherlands	45	2.2k 1.2×	597 0.5×	1.4k 1.3×	371 0.5×	807 1.4×	134	7.3k
Claire F. Verschraegen United States	46	1.5k 0.8×	3.0k 2.7×	2.0k 1.8×	876 1.3×	1.1k 1.9×	267	6.9k
Klaas Hoekman Netherlands	41	999 0.5×	2.4k 2.2×	1.9k 1.8×	470 0.7×	437 0.8×	102	5.2k
Hiroshi Takita United States	37	1.5k 0.8×	1.5k 1.4×	608 0.6×	571 0.8×	685 1.2×	158	3.6k
Roy B. Jones United States	43	765 0.4×	2.5k 2.2×	970 0.9×	791 1.2×	396 0.7×	176	6.6k
Cornelis F.M. Sier Netherlands	43	678 0.4×	2.1k 1.9×	1.9k 1.7×	763 1.1×	690 1.2×	130	5.4k
Mark L. Bernstein United States	48	2.7k 1.5×	1.8k 1.6×	2.2k 2.0×	450 0.7×	1.1k 2.0×	184	7.5k
Toshiaki Morikawa Japan	36	2.3k 1.3×	1.5k 1.4×	818 0.7×	475 0.7×	1.6k 2.9×	204	4.9k

Countries citing papers authored by Peter M. Anderson

Since Specialization

Citations

This map shows the geographic impact of Peter M. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Anderson more than expected).

Fields of papers citing papers by Peter M. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Anderson. The network helps show where Peter M. Anderson may publish in the future.

Co-authorship network of co-authors of Peter M. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Anderson. A scholar is included among the top collaborators of Peter M. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Anderson. Peter M. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meyers, Paul A., Noah Federman, Najat C. Daw, et al.. (2024). Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. Journal of Clinical Oncology. 42(31). 3725–3734. 13 indexed citations

Kairemo, Kalevi, Mohamed A. Gouda, Lars Buschhorn, et al.. (2023). Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open. 8(4). 101575–101575. 1 indexed citations

Anderson, Peter M., Brian D. Crompton, Kelly Klega, et al.. (2023). Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research. 29(9). 1689–1697. 15 indexed citations

Smrke, Alannah, et al.. (2021). The perplexing role of immuno-oncology drugs in osteosarcoma. Journal of bone oncology. 31. 100400–100400. 7 indexed citations

Babiker, Hani M., Erkut Borazanci, Vivek Subbiah, et al.. (2020). 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours. Annals of Oncology. 31. S711–S712. 2 indexed citations

Ludwig, Joseph A., Noah Federman, Peter M. Anderson, et al.. (2020). 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. Annals of Oncology. 31. S972–S972. 10 indexed citations

Hayes‐Jordan, Andrea, Brian A. Coakley, L. Xiao, et al.. (2018). Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Annals of Surgical Oncology. 25(4). 872–877. 55 indexed citations

Anderson, Peter M.. (2017). Immune Therapy for Sarcomas. Advances in experimental medicine and biology. 995. 127–140. 10 indexed citations

Osborne, E.M., Tina M. Briere, Andrea Hayes‐Jordan, et al.. (2015). Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor. Radiotherapy and Oncology. 119(1). 40–44. 28 indexed citations

10.

Rodriguez, Carlos O., Dennis W. Wilson, Katherine A. Skorupski, et al.. (2009). Aerosol Gemcitabine: Preclinical Safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23(4). 197–206. 35 indexed citations

11.

Costelloe, Colleen M., Homer A. Macapinlac, John E. Madewell, et al.. (2009). ¹⁸F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma. Journal of Nuclear Medicine. 50(3). 340–347. 143 indexed citations

12.

Angulo, Guillermo De, Carrie Yuen, Shana L. Palla, Peter M. Anderson, & Patrick A. Zweidler‐McKay. (2007). Absolute lymphocyte count is a novel prognostic indicator in ALL and AML. Cancer. 112(2). 407–415. 92 indexed citations

13.

Rodriguez, Vilmarie, et al.. (2005). Low toxicity and efficacy of ¹⁵³samarium‐EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatric Transplantation. 9(1). 122–126. 7 indexed citations

14.

Ten, Rosa, et al.. (2002). Interleukin-2 liposomes for primary immune deficiency using the aerosol route. International Immunopharmacology. 2(2-3). 333–344. 36 indexed citations

15.

Anderson, Peter M., Gregory A. Wiseman, Angela Dispenzieri, et al.. (2002). High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases. Journal of Clinical Oncology. 20(1). 189–196. 75 indexed citations

16.

Frost, Jami D., Jacquelyn A. Hank, Gregory H. Reaman, et al.. (1997). A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer. 80(2). 317–333. 120 indexed citations

17.

Khanna, Chand, Peter M. Anderson, Diane E. Hasz, et al.. (1997). Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer. 79(7). 1409–1421. 105 indexed citations

18.

Saltzman, Daniel A., Charles P. Heise, Diane E. Hasz, et al.. (1996). Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent. Cancer Biotherapy and Radiopharmaceuticals. 11(2). 145–153. 80 indexed citations

19.

Katsanis, Emmanuel, Bruce R. Blazar, María A. Bausero, Roland Günther, & Peter M. Anderson. (1994). Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. Journal of Pediatric Surgery. 29(4). 538–542. 11 indexed citations

20.

Anderson, Peter M., et al.. (1994). Cytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γ. Cytokine. 6(1). 92–101. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact